sc291
sc291: sourced relationships with 1 company · 2 clinical trials tracked.
sc291 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could sc291 → SANA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Sana Biotechnology, Inc. (SANA) Non Hodgkin Lymphoma; Lupus Erythematosus | Phase 1 |
Clinical Trial Registry Records (2)
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Subjects With Severe Relapsed or Refractory Autoimmune Diseases (GLEAM)
Primary endpoint: Evaluate safety and tolerability of SC291
A Phase 1 Study Evaluating SC291, a Hypoimmune, Allogeneic CD19-directed CAR T Cell Therapy, in Relapsed and/or Refractory B-cell Malignancies (ARDENT)
Primary endpoint: Evaluate safety and tolerability of SC291
Frequently asked questions
Which companies have sourced relationships with sc291?
sc291 has dated SEC/FDA relationship records for Sana Biotechnology, Inc..
How many clinical trials involve sc291?
BioSniper tracks 2 clinical trials involving sc291.